Learn about Elacestrant, an oral selective estrogen receptor degrader (SERD) for ER-positive, HER2-negative advanced breast cancer, its uses, efficacy, and side effects.
Elacestrant: 6 Key Points About This Oral Breast Cancer Therapy
Elacestrant is an innovative oral medication representing a significant advancement in the treatment landscape for certain types of advanced breast cancer. As a selective estrogen receptor degrader (SERD), it offers a new therapeutic option for patients who have previously undergone endocrine therapy. Understanding its mechanism, indications, and considerations is crucial for both patients and healthcare providers.
1. Understanding Elacestrant: A Novel Approach to Breast Cancer Treatment
Elacestrant is classified as an oral Selective Estrogen Receptor Degrader (SERD). Its primary function involves binding to the estrogen receptor (ER) within cancer cells and promoting its degradation. This action prevents estrogen from attaching to the receptor, thereby inhibiting the growth and division of ER-positive breast cancer cells. Unlike some older SERDs, Elacestrant is administered orally, offering a convenient alternative for patients. It is particularly relevant for cancers that have developed mutations in the ESR1 gene, which can lead to resistance to conventional endocrine therapies.
2. Indications and Target Patient Population for Elacestrant
Elacestrant is indicated for the treatment of postmenopausal women, or men, with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or metastatic breast cancer. This treatment is specifically for patients whose disease has progressed following at least one line of endocrine therapy in the metastatic setting. A key aspect of its indication is for patients whose tumors harbor an ESR1 mutation, as these mutations are frequently associated with resistance to standard endocrine treatments and Elacestrant has demonstrated particular efficacy in this subgroup.
3. Administration and Dosage Guidelines for Elacestrant
Elacestrant is an oral medication taken once daily. The recommended dosage is typically 345 mg, administered with food, around the same time each day. It is important for patients to swallow the tablets whole and not to chew, crush, or split them. Should a dose be missed, it should be taken as soon as remembered, unless it is almost time for the next dose, in which case the missed dose should be skipped. Dose modifications may be necessary based on individual patient tolerance and the occurrence of side effects, which should always be managed under the guidance of a healthcare professional.
4. Clinical Efficacy and Trial Outcomes of Elacestrant
The efficacy of Elacestrant was primarily established through the EMERALD Phase 3 clinical trial. In this study, Elacestrant demonstrated a statistically significant improvement in progression-free survival (PFS) compared to standard endocrine therapy (fulvestrant or an aromatase inhibitor). The benefit was particularly pronounced in patients whose tumors had an ESR1 mutation, showing a longer median PFS. These results indicate that Elacestrant offers a meaningful clinical benefit for the specified patient population, providing a new option where previous endocrine therapies may have failed.
5. Recognizing Potential Side Effects of Elacestrant
As with any medication, Elacestrant can be associated with side effects. Common adverse reactions observed in clinical trials included nausea, fatigue, vomiting, musculoskeletal pain, elevated cholesterol levels (hypercholesterolemia), abdominal pain, hot flashes, constipation, and headache. More serious, though less common, side effects could include liver function abnormalities and thromboembolic events. Patients are advised to discuss any side effects with their healthcare provider, who can offer strategies for management and determine if dose adjustments are necessary.
6. Important Considerations for Patients and Healthcare Professionals
When considering treatment with Elacestrant, several factors are important. Regular monitoring of liver function tests and lipid profiles (cholesterol levels) is recommended during treatment. Healthcare providers should also be aware of potential drug interactions, especially with strong CYP3A4 inhibitors or inducers, which can affect the concentration of Elacestrant in the body. Elacestrant is not recommended for use during pregnancy or breastfeeding due to potential harm to a fetus or infant. Comprehensive patient education regarding adherence, potential side effects, and the importance of regular follow-up is essential.
Summary
Elacestrant is an oral selective estrogen receptor degrader (SERD) approved for treating ER-positive, HER2-negative advanced or metastatic breast cancer, particularly in patients with ESR1 mutations who have progressed on prior endocrine therapy. Its mechanism involves degrading the estrogen receptor, thereby inhibiting cancer cell growth. Clinical trials have demonstrated its efficacy in improving progression-free survival. While generally manageable, patients may experience side effects like nausea and fatigue. It is administered once daily with food, and close monitoring and communication with healthcare providers are crucial for safe and effective use.